Argent Trust Co boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 845.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,355 shares of the pharmaceutical company’s stock after acquiring an additional 52,181 shares during the quarter. Argent Trust Co’s holdings in GlaxoSmithKline were worth $2,230,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Norway Savings Bank raised its holdings in GlaxoSmithKline by 14.9% during the 4th quarter. Norway Savings Bank now owns 4,133 shares of the pharmaceutical company’s stock worth $158,000 after buying an additional 535 shares during the period. Boenning & Scattergood Inc. raised its holdings in GlaxoSmithKline by 71.0% during the 4th quarter. Boenning & Scattergood Inc. now owns 55,061 shares of the pharmaceutical company’s stock worth $2,104,000 after buying an additional 22,867 shares during the period. Moody National Bank Trust Division raised its holdings in GlaxoSmithKline by 1.5% during the 4th quarter. Moody National Bank Trust Division now owns 34,108 shares of the pharmaceutical company’s stock worth $1,303,000 after buying an additional 508 shares during the period. Cullinan Associates Inc. raised its holdings in GlaxoSmithKline by 27.2% during the 4th quarter. Cullinan Associates Inc. now owns 29,500 shares of the pharmaceutical company’s stock worth $1,127,000 after buying an additional 6,300 shares during the period. Finally, Waldron Private Wealth LLC raised its holdings in GlaxoSmithKline by 10.0% during the 3rd quarter. Waldron Private Wealth LLC now owns 5,500 shares of the pharmaceutical company’s stock worth $220,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 10.89% of the company’s stock.
Several analysts have issued reports on GSK shares. ValuEngine upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Wolfe Research started coverage on GlaxoSmithKline in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, October 29th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, November 27th. Finally, Barclays downgraded GlaxoSmithKline from an “overweight” rating to an “equal weight” rating and set a $36.95 price objective on the stock. in a report on Tuesday, December 4th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $41.71.
Shares of GSK opened at $40.37 on Thursday. The stock has a market capitalization of $100.54 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 2.15 and a beta of 0.79. GlaxoSmithKline plc has a fifty-two week low of $35.78 and a fifty-two week high of $42.36. The company has a debt-to-equity ratio of 5.52, a quick ratio of 0.51 and a current ratio of 0.75.
GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.70 by $0.09. The company had revenue of $10.55 billion for the quarter, compared to the consensus estimate of $9.85 billion. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. On average, sell-side analysts expect that GlaxoSmithKline plc will post 2.94 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 22nd will be issued a $0.597 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, February 21st. This represents a $2.39 dividend on an annualized basis and a dividend yield of 5.92%. GlaxoSmithKline’s dividend payout ratio is currently 60.76%.
TRADEMARK VIOLATION NOTICE: “Argent Trust Co Raises Holdings in GlaxoSmithKline plc (GSK)” was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://macondaily.com/2019/02/14/argent-trust-co-raises-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: What is a short straddle?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.